This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
Dyne Therapeutics, Inc., a clinical-stage company specializing in treatments for genetically driven neuromuscular diseases, has announced a public offering of $200 million in common stock, with an ...
Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 ...
Dyne Therapeutics, Inc. announced the successful completion of its public offering of 27,878,788 shares of common stock at a price of $8.25 per share, generating approximately $230 million in gross ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback